Introduction {#Sec1}
============

Placental implantation in which there is abnormally firm adherence to the uterine wall is defined as placenta increta as well as related conditions like placenta accreta and percreta \[[@CR1]\]. This is a challenging obstetrical problem causing severe maternal morbidity like uterine perforation, infection and severe hemorrhage. Severe bleeding is the single most significant cause of maternal death worldwide \[[@CR2]\]. Invasive placentation affects \~2% of all singleton deliveries \[[@CR3]\]. Probably due to the increasing rates of caesarean deliveries in most countries, the incidence has increased in recent years \[[@CR4]\]. Because previous studies reported better maternal survival with hysterectomy than with uterus preserving treatment modalities, a hysterectomy has long been the initial therapy \[[@CR2]\]. However, preserving uterine function is important to preserve reproductive potential.

Several case reports indicate that uterus preserving treatment may result in successful management of invasive placentation. In the current literature, different uterus preserving treatment modalities are described: expectant management, embolization of the uterine arteries, methotrexate therapy and uterus preserving surgery \[[@CR2], [@CR5], [@CR6]\]. In 2007, Timmermans et al. \[[@CR6]\] reviewed 48 case reports about the obstetric outcome after expectant management, embolization of the uterine arteries and methotrexate therapy for invasive placentation. They concluded that it should only be considered in highly selected cases and that no proof was found for a first choice uterus preserving treatment modality.

We present a literature review to evaluate failure rates (secondary hysterectomy or maternal mortality) and success rates (subsequent menstruation or pregnancy) after different uterus preserving treatment modalities in women with invasive placentation.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

A computer-aided search of Medline and Embase was carried out. The following search terms were used: 'placenta accreta', 'placenta increta', 'placenta percreta' and 'conservative treatment' ([Appendix 1](#Sec20){ref-type="sec"}). The reference lists of identified studies were searched for additional relevant studies.

Inclusion criteria {#Sec4}
------------------

Every study design that was published in English, German or Dutch was considered for inclusion. Given that randomized-controlled trials and large observational cohort studies that can be used to define best practice are lacking, studies of any design were obtained for further evaluation. Studies were included if they described the course of uterus preserving treatment modalities for patients with placenta accreta, increta or percreta. Uterus preserving treatment modalities were defined as initial therapy consisting of: expectant management (expectant management for patients who delivered vaginally or closing the hysterectomy as caesarean delivery occurred), embolization of the uterine arteries, methotrexate therapy or uterus preserving surgery. Because we investigated uterus preserving techniques in which the placenta was left in situ, we limited uterus preserving surgery to hemostatic sutures, arterial ligation and balloon tamponade. Diagnoses of invasive placentation must be made upon clinical suspicion, ultrasound or magnetic resonance imaging (MRI). Studies were excluded if patients underwent a hysterectomy as initial management, or if patients were approached conservatively because caesarean hysterectomy was considered too dangerous or difficult.

Selection of studies {#Sec5}
--------------------

The first reviewer (CN) screened the titles and abstracts of identified articles for eligibility. Papers that seemed to be relevant were obtained, and the full text articles were screened for inclusion. If there was doubt about the suitability of the studies, they were discussed with two other independent reviewers (TP, TE).

Data extraction and analysis {#Sec6}
----------------------------

The eligible articles were summarized in a data extraction form, including the following items: obstetric characteristics, maternal morbidity/mortality and subsequent pregnancy/menstruation. Obstetric characteristics included gestational age and mode of delivery. Maternal morbidity/mortality was defined as severe vaginal bleeding (need for blood transfusion or \>1,000 ml blood loss), sepsis (definition used according to the definitions of the authors in the different studies), a secondary hysterectomy or maternal mortality.

Data were presented as numbers and as percentages (rates). Rates were calculated using the reported number of a specific item as the numerator divided by all studies that reported that specific item as denominator.

Data were summarized separately for expectant management, methotrexate therapy, embolization of the uterine arteries and uterus preserving surgery with distinction between forms of invasive placentation (placenta accreta, increta or percreta).

Data extraction and analysis was done by the first reviewer (CN).

Results {#Sec7}
=======

We identified 1,477 articles, of which 270 were potentially relevant after removing duplicates and screening the title and abstract. Applying our inclusion criteria led to the inclusion of 10 cohort studies and 50 case series or case reports describing 434 patients. Of them, 295 patients treated with expectant management, 45 with embolization of the uterine arteries, 17 with methotrexate therapy and 77 with uterus preserving surgery were reported (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Literature search

Expectant management (Table [1](#Tab1){ref-type="table"}) {#Sec8}
---------------------------------------------------------

Twenty articles described 295 patients with invasive placentation approached with expectant management \[[@CR7]--[@CR25]\]: a secondary hysterectomy occurred in 55/287 (19%), maternal mortality in 1/295 (0.3%), a subsequent menstruation in 44/49 (90%) and a subsequent pregnancy in 24/36 (67%).Table 1Expectant managementStudyDesignFollow up*N*Obstetric characteristicsMaternal morbidity/mortalitySubsequent menstruationSubsequent pregnancyGestational age (weeks)Mode of deliverySevere vaginal bleedingSepsisSecondary hysterectomy (indication)Maternal mortalityPlacenta accreta Davis \[[@CR7]\]Case report5 months1NRCSNRNR1 (hemorrhage, pain)000 Bennett \[[@CR8]\]Case series4 years128Breech extr1NR00NR14 years137Vacuum0000NR11 year115VaginallyNRNR00NR1 Chianq \[[@CR9]\]Case report43 days135CS1100NRNR Jwarah \[[@CR10]\]Case report2 years139Vaginally000011 Kayem \[[@CR11]\]Retr cohort5 years^a^1933 ± 6CS, vaginally16/193/192/19 (hemorrhage)0/19NR2/7 (12 NR) Kayem \[[@CR12]\]Case seriesNR142CS0000NR1NR139CS0000NR1NR138CS0000NR1NR138CS0000NRNRNR137CS101 (hemorrhage)000 Komulainen \[[@CR13]\]Case series5 years142Vaginally100011134Vaginally100011 Sinha \[[@CR14]\]Case series9 days137CS101 (hemorrhage)0007 days120Vaginally1000NRNR4 weeks117Vaginally1000NRNR Matsumura \[[@CR15]\]Case series6 weeks^b^526--35CS, vaginally0/50/50/50/55/5NR Taylor \[[@CR16]\]Case report13 weeks139Vaginally00001NR Hatfield \[[@CR17]\]Case series6 weeks^b^1TermVaginally0000NRNR13 weeks^b^123NR00001NR Sentilhes \[[@CR18]\]Retr cohortNR167NRCS, vaginally109/167^a^8/16736/167 (hemorrhage)1/167NRNR Bretelle \[[@CR19]\]Retr cohortNR26NRNR10/26^a^NR5/26 (hemorrhage)0/2621/211/1 (20 NR) Provansal \[[@CR21]\]Retr cohortNR46NRNR6/46NR6/46 (hemorrhage)0/4612/1212/14 Total282148/28012/20552/2821/28243/4624/3453%6%18%0.3%93%71%Placenta increta Sinha \[[@CR14]\]Case report10 days138CS101 (hemorrhage)0NRNR Panoskaltsis \[[@CR22]\]Case report9 months139Forceps10001NR Total22/20/21/20/21/1NR100%0%50%0%100%NRPlacenta percreta O'Brien \[[@CR23]\]Retr cohort8NRNR0/8NRNR0/8NRNR Lee \[[@CR24]\]Case report15 days117CS/laparotomy1000NRNR Veenstra \[[@CR25]\]Case reportNR125Vaginally101 (hemorrhage)000 Teo \[[@CR26]\]Case report9 days136CS101 (hemorrhage)000 Total113/80/32/30/110/20/238%0%67%0%0%0%Placenta accreta, increta, percreta Total295153/29012/21055/2871/29544/4924/3653%6%19%0.3%90%67%*N* number of patients, *NR* not reported, *CS* caesarean section^a^In some patients, hypogastric artery ligation and/or uterine artery embolizations were performed^b^Placentas were successfully removed transvaginally \>6 weeks postpartum

Embolization of the uterine arteries (Table [2](#Tab2){ref-type="table"}) {#Sec9}
-------------------------------------------------------------------------

Sixteen articles reported 45 patients managed with embolization of the uterine arteries \[[@CR12], [@CR26]--[@CR40]\]: a secondary hysterectomy occurred in 8/45 (18%), a subsequent menstruation in 8/13 (62%) and a subsequent pregnancy in 5/33 (15%). All patients survived until the end of follow up.Table 2Embolization of the uterine arteriesStudyDesignFollow up*N*Obstetric characteristicsMaternal morbidity/mortalitySubsequent menstruationSubsequent pregnancyGestational age (weeks)Mode of deliverySevere vaginal bleedingSepsisSecondary hysterectomy (indication)Maternal mortalityPlacenta accreta Kayem \[[@CR27]\]Case report3 years1TermVaginally0000NR1 Kayem \[[@CR12]\]Case seriesNR139CS1000NR1NR138CS1100NRNR Sivan \[[@CR28]\]Retr cohortNR23NRCS2/23NR2/23 (hemorrhage)0NR3/23 Total264/261/32/260/26NR5/2515%33%8%0%NR20%Placenta increta Breathnach \[[@CR29]\]Case report12 weeks^a^136CS01001NR Takeda \[[@CR30]\]Case report62 days18Curettage00001NR Liao \[[@CR31]\]Case report112Curettage101 (hemorrhage)000 Total31/31/31/30/32/30/133%33%33%0%67%0%Placenta percreta Clement \[[@CR32]\]Case series4 months137CS1NR00104 months125CS000010 Bennett \[[@CR33]\]Case series12 months131CS10001NR4 months136CS00001NR Tan \[[@CR34]\]Retr cohort1 month5NRCS3/5NR1/5 (hemorrhage)0/5NRNR Diop \[[@CR35]\]Case reportNR138CS0NR00NRNR Luo \[[@CR36]\]Case report49 days132CS101 (hemorrhage)000 Tseng \[[@CR37]\]Case report5 weeks19NR101 (hemorrhage)000 Dinkel \[[@CR38]\]Case report3 months132CS101 (hemorrhage)000 Yee \[[@CR39]\]Case report164 days134CS10001NR Descargues \[[@CR40]\]Case report1 year136CSNRNR0010 Butt \[[@CR41]\]Case report15 days^a,b^130CS101 (hemorrhage)000 Total1610/150/85/160/166/100/767%0%31%0%60%0%Placenta accreta, increta, percreta Total4515/442/148/450/458/135/3334%14%18%0%62%15%*N* number of patients, *NR* not reported, *CS* caesarean section^a^The placenta was successfully removed transvaginally \>6 weeks postpartum^b^Methotrexate was given intra- and/or postoperatively

Methotrexate therapy (Table [3](#Tab3){ref-type="table"}) {#Sec10}
---------------------------------------------------------

Fifteen articles showed 17 patients receiving methotrexate therapy \[[@CR21], [@CR41]--[@CR54]\]: a secondary hysterectomy occurred in 1/16 (6%), a subsequent menstruation in 4/5 (80%) and a subsequent pregnancy in 1/2 (50%). All patients from the studies survived until the end of follow up.Table 3Methotrexate therapyStudyDesignFollow up*N*Obstetric characteristicsMaternal morbidity/mortalitySubsequent menstruationSubsequent pregnancyGestational age (weeks)Mode of deliverySevere vaginal bleedingSepsisSecondary hysterectomy (indication)Maternal mortalityPlacenta accreta Morken \[[@CR42]\]Case report14 days130CS0000NRNR Cole \[[@CR43]\]Case report6 h^a^1NRVaginally0NRNR0NRNR Total20/20/10/10/2NRNR0000NRNRPlacenta increta Panoskaltsis \[[@CR22]\]Case report12 months134Vaginally00001NR Crespo \[[@CR44]\]Case report7 months^a^140CS0000NRNR Wehbe \[[@CR45]\]Case report2 months1NRVaginallyNRNR00NRNR Zepiridis \[[@CR46]\]Case series12 weeks^a^1NRNR1000NRNR10 weeks^a^138Vaginally0000NRNR7 weeks^b^1NRNR1NR00NRNR Adair \[[@CR47]\]Case report16 weeks^a^1NRVaginally110000 Endo \[[@CR48]\]Case report2 months139Vaginally00001NR Total83/71/60/80/82/30/143%17%0%0%67%0%Placenta percreta Otsubo \[[@CR49]\]Case report6 months136CS0000NRNR Heiskanen \[[@CR50]\]Case report16 months129Vaginally00001NR Legro \[[@CR51]\]Case report24 months135Vaginally000011 Nijman \[[@CR52]\]Case report14 weeks1NRVaginally0000NRNR Henrich \[[@CR53]\]Case report10 weeks^a^136CS0000NRNR Sonin \[[@CR54]\]Case report11 months1TermVaginally0000NRNR Valayatham \[[@CR55]\]Case report66 days136CS0000NRNR Total71/70/71/70/72/21/114%0%14%0%100%100%Placenta accreta, increta, percreta Total174/161/141/160/174/51/225%7%6%0%80%50%*N* number of patients, *NR* not reported, *CS* caesarean section^a^The placenta passed vaginally at the end of follow up^b^The placenta was removed by curettage/manual removal at the end of follow up

Uterus preserving surgery (Table [4](#Tab4){ref-type="table"}) {#Sec11}
--------------------------------------------------------------

Eleven articles presented 77 patients with uterus preserving surgery \[[@CR55]--[@CR65]\]: a secondary hysterectomy occurred in 24/77 (31%), maternal mortality in 2/55 (4%), a subsequent menstruation in 28/34 (82%) and a subsequent pregnancy in 19/26 (73%).Table 4Uterus preserving surgery: hemostatic sutures or arterial ligationStudyDesignFollow up*N*Obstetric characteristicsMaternal morbidity/mortalitySubsequent menstruationSubsequent pregnancyGestational age (weeks)Mode of deliverySevere vaginal bleedingSepsisSecondary hysterectomy (indication)Maternal mortalityPlacenta accreta Arduini \[[@CR56]\]Retr cohortNR9NRCS5/90/90/90/9NRNR Ferrazzani \[[@CR57]\]Case report10 months135CS00001NR Hung \[[@CR58]\]Case report68 days129CS0000NRNR Mechery \[[@CR59]\]Case report3 weeks132CS1NR^a^1 (infection)^a^000 Shahin \[[@CR60]\]Prosp cohort1 year3234--39CS8/320/248/32 (hemorrhage)2/3220/2418/24 Verspyck \[[@CR61]\]Retr cohort13 months626--32CS5/6^b^NR1/6 (hemorrhage)0/65/61/1Read \[[@CR62]\]Retr cohort18 days22NRCS, vaginally[\|nr]{.smallcaps}NR14/22 (hemorrhage)NRNRNR Total7219/500/3524/722/5026/3219/26\|38%35%33%4%81%73%Placenta percreta Wang \[[@CR63]\]Case report6 months131CS^c^1^d^0001NR Caliskan \[[@CR64]\]Case series6 months131CS00001NR6 months138CS1NR00NRNR Nagy \[[@CR65]\]Case report10 days128CS^c^1000NRNR Gupta \[[@CR66]\]Case report10 days136CS^c^1000NRNR Total54/50/40/50/52/2NR80%0%0%0%100%NRPlacenta accreta and percreta Total7723/550/3924/772/5528/3419/2642%0%31%4%82%73%*N* number of patients, *NR* not reported, *CS* caesarean section^a^Infection was not further specified^b^In one patient an immediate secondary embolization was necessary to control a persistent hemorrhage despite an arterial ligation procedure^c^Methotrexate was given intra- and/or postoperatively^d^Uterine rupture secondary to placenta percreta

Comment {#Sec12}
=======

The aim of the current review was to evaluate failure and success rates of women with invasive placentation managed with different uterus preserving treatment modalities. The most important gain of uterus preserving treatment is preserving reproductive material. Our results show varying failure and success rates among the different uterus preserving treatment modalities: a secondary hysterectomy was needed in 6--31% and maternal mortality occurred in 0--4% (failure rates); menstruation followed in 62--90% and a subsequent pregnancy occurred in 15--73% (success rates). Our results are based on descriptive data only (case series, case reports and a few cohort studies). Therefore, it is not possible to compare different uterus preserving treatment modalities and no conclusions about the superiority of any modality can be drawn.

Uterus preserving treatment modalities in general {#Sec13}
-------------------------------------------------

Given the risk of substantial morbidity (including coagulopathy, severe hemorrhage, infection, sepsis, ureteral injury, need for blood transfusion/hysterectomy) and mortality, uterus preserving treatment may have a role in carefully selected patients who desire future fertility \[[@CR66]\]. The patient should be counselled about the risk of hysterectomy, blood transfusion and even death. Prophylactic antibiotics are generally administrated to prevent infection \[[@CR18]\]. When conservative management is successful, it results in gradual resorption of the placenta or delayed delivery of the placenta \[[@CR15], [@CR17], [@CR28]\]. Due to the risk of severe hemorrhage, all obstetric units and practitioners must have the facilities, personnel, and equipment in place to manage this emergency properly and a multidisciplinary approach is recommended \[[@CR2], [@CR67]\].

Expectant management {#Sec14}
--------------------

Whether adjuvant therapy in addition to expectant management alone is beneficial is uncertain. Timmermans et al. \[[@CR6]\] reported 60 cases with abnormally invasive placentation. Expectant management was successful in 48 cases, but adjuvant therapy (uterine arterial embolization and methotrexate therapy) was employed in 34 cases.

Uterine arterial embolization {#Sec15}
-----------------------------

Arterial embolization is a viable treatment for postpartum bleeding. A patient with stable vital sings and persistent bleeding, especially if the rate of loss is not excessive, may be a candidate for arterial embolization \[[@CR2]\]. A previous Cochrane review \[[@CR68]\] compared uterine arterial embolization with hysterectomy for symptomatic uterine fibroids. They concluded that uterine arterial embolization offers an advantage over hysterectomy with regard to a shorter hospital stay and a quicker return to routine activities. Specific complications from this procedure include iliac artery thrombosis, uterine necrosis or sepsis resulting in multiple organ failure. In addition, non-target embolization can cause ischaemic damage to other organs \[[@CR69]\].

Methotrexate therapy {#Sec16}
--------------------

Methotrexate disrupts the folic acid pathway in rapidly dividing cells such as trophoblasts. However, the proliferation of trophoblasts in the later stages of pregnancy has been shown to have no role in placental growth \[[@CR66]\]. Consequently, the use of methotrexate may not reduce placental volume. This therapy might even be harmful: methotrexate has a immunosuppressive role and therefore could increase the risk of infection or even sepsis, which is already increased in patients with abnormal adherent placentation. Other specific adverse effects are methotrexate-related pancytopenia and nephrotoxicity \[[@CR70], [@CR71]\].

Uterus preserving surgery {#Sec17}
-------------------------

Uterine compression sutures function in a manner similar to manual compression and are placed to prevent uterine relaxation due to the retained placenta \[[@CR72]\]. Arterial occlusion (arterial ligation or balloon tamponade) is indicated for the management of bleeding. In some cases, a combination of both techniques was used \[[@CR58]\]. Because we investigated uterus preserving techniques in which the placenta was left in situ, we limited uterus preserving surgery to hemostatic sutures, arterial ligation and balloon tamponade. Other surgical techniques focussing on resection of the invasive placentation are described \[[@CR73]\]. In addition to technical advances in vascular control and tissue repair, these surgical resection techniques may contribute to future better uterus preserving surgical options.

Limitations {#Sec18}
-----------

Due to the descriptive data, this review has a narrative character. The biggest limitation of descriptive data gathered from published case reports and series is that these data are subject to publication bias. The data may be misleading, giving uterus preserving treatment modalities a higher than true success rate. People tend to write up case reports of cases they did that went well; they are less likely to write up the case report about the patients who died or had major complications from uterus preserving treatment. Severe complications are prone to being underreported.

In addition, the cases are limited by the ability to fully determine correct documentation of correct pregnancy or long-term outcome/complications of these pregnancies. In most case reports, data are lacking, which make it difficult to draw conclusions.

Furthermore, categorizing each case specifically based upon the type of uterus preserving treatment modality is difficult since there are varying degrees of placental attachment abnormalities and varying amounts of the placenta which adhere abnormally to the uterus. The uterine preserving treatment modality is a surgical decision based upon particular characteristics of the problem and the expertise of the surgeon. The choice of uterus preserving treatment modality is intricately linked with the degree of placental volume involved. Specific uterus preserving treatment modalities may have the best outcome because the volume of placental involvement is less. Bad outcomes may be employed in large volume placental involvement. The results may simply be a function of disease severity.

However, evaluation of uterus preserving treatment is important and of great clinical use because of the possibility of a subsequent pregnancy. Large-scale studies are required using prospective and repeated measure designs to further evaluate the safety, efficacy and fertility effects.

Conclusion {#Sec19}
----------

This review indicates that different uterus preserving treatment modalities may be effective in managing invasive placentation. Despite the extensive review of the literature, no conclusions about the superiority of any modality can be drawn.
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Appendix 1 {#Sec20}
==========

Search Medline {#Sec21}
--------------

(((((("placenta"\[Title/Abstract\]) OR "placentas"\[Title/Abstract\]) OR "placenta's"\[Title/Abstract\])) AND (((((((("increta"\[Title/Abstract\] OR "increta/percreta"\[Title/Abstract\])) OR "accreta"\[Title/Abstract\]) OR "accreta/increta/percreta"\[Title/Abstract\]) OR "accreta/increta"\[Title/Abstract\]) OR "accreta/percreta/increta"\[Title/Abstract\])) OR ("percreta"\[Title/Abstract\] OR "percreta/increta"\[Title/Abstract\] OR "percreta involving"\[Title/Abstract\] OR "percreta placenta"\[Title/Abstract\] OR "percreta presenting"\[Title/Abstract\] OR "percreta, placenta"\[Title/Abstract\])))) AND ((((((((("expectative"\[Title/Abstract\] OR "expectative approach"\[Title/Abstract\] OR "expectative attitude"\[Title/Abstract\] OR "expectative management"\[Title/Abstract\] OR "expectative policy"\[Title/Abstract\] OR "expectative treatment"\[Title/Abstract\])) OR "expectatively"\[Title/Abstract\]) OR "expectatory"\[Title/Abstract\])) OR ((("conservative"\[Title/Abstract\]) OR conventional\[Title/Abstract\]) OR traditional\[Title/Abstract\])) OR (("hysterectomy"\[Title/Abstract\]) OR "hysterectomies"\[Title/Abstract\])) OR ((((((((((((("surgery"\[Title/Abstract\]) OR "surgeries"\[Title/Abstract\]) OR "resection"\[Title/Abstract\]) OR "resections"\[Title/Abstract\]) OR "resections"\[Title/Abstract\]) OR "surgical"\[Title/Abstract\]) OR "surgically"\[Title/Abstract\]) OR "procedure"\[Title/Abstract\]) OR "procedures"\[Title/Abstract\]) OR "operation"\[Title/Abstract\]) OR "operations"\[Title/Abstract\]) OR "manipulation"\[Title/Abstract\]) OR "manipulations"\[Title/Abstract\])) OR ((((((((((((((((("treatment"\[Title/Abstract\]) OR "treatments"\[Title/Abstract\]) OR "care"\[Title/Abstract\]) OR "procedure"\[Title/Abstract\]) OR "procedure"\[Title/Abstract\]) OR "procedures"\[Title/Abstract\]) OR "strategy"\[Title/Abstract\]) OR "strategies"\[Title/Abstract\]) OR "usage"\[Title/Abstract\]) OR "way"\[Title/Abstract\]) OR "management"\[Title/Abstract\]) OR "managements"\[Title/Abstract\]) OR "guidance"\[Title/Abstract\]) OR "guidances"\[Title/Abstract\]) OR "support"\[Title/Abstract\]) OR "therapy"\[Title/Abstract\]) OR "therapies"\[Title/Abstract\])).

Search Embase {#Sec22}
-------------

(placenta:ab,ti OR placentas:ab,ti OR placentas:ab,ti) AND (increta:ab,ti OR accreta:ab,ti OR percreta:ab,ti) AND (expectative:ab,ti OR approach:ab,ti OR attitude:ab,ti OR management:ab,ti OR policy:ab,ti OR treatment:ab,ti OR expectatively:ab,ti OR expectatory:ab,ti OR conservative:ab,ti OR conventional:ab,ti OR traditional:ab,ti OR hysterectomy:ab,ti OR hysterectomies:ab,ti OR surgery:ab,ti OR surgeries:ab,ti OR resection:ab,ti OR resections:ab,ti OR resections:ab,ti OR surgical:ab,ti OR surgically:ab,ti OR procedure:ab,ti OR procedures:ab,ti OR operation:ab,ti OR operations:ab,ti OR manipulation:ab,ti OR manipulations:ab,ti OR treatment:ab,ti OR treatments:ab,ti OR care:ab,ti OR procedure:ab,ti OR procedure:ab,ti OR procedures:ab,ti OR strategy:ab,ti OR strategies:ab,ti OR usage:ab,ti OR way:ab,ti OR management:ab,ti OR managements:ab,ti OR guidance:ab,ti OR guidances:ab,ti OR support:ab,ti OR therapy:ab,ti OR therapies:ab,ti).
